Coronavirus canSAR – a Data-Driven, AI-Enabled, Drug Discovery Resource for the Research Community

We describe an AI-enabled, integrated Coronavirus drug discovery knowledgebase, free for the research community. Its goal is to make accessible up to date information relevant to drug discovery for SARS-CoV-2 and other coronaviruses. It builds on great knowledge from across therapeutic areas and provides unbiased, systematic, objective information to empower the international effort.

[1]  Benjamin J. Polacco,et al.  A SARS-CoV-2 Protein Interaction Map Reveals Targets for Drug-Repurposing , 2020, Nature.

[2]  Asher Mullard.  Coordinating the COVID-19 pipeline , 2020, Nature Reviews Drug Discovery.

[3]  Yechun Xu,et al.  Structure of Mpro from COVID-19 virus and discovery of its inhibitors , 2020, bioRxiv.

[4]  Paul Workman,et al.  canSAR: update to the cancer translational research and drug discovery knowledgebase , 2018, Nucleic Acids Res..

[5]  C. Sander,et al.  Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets , 2018, Nature Genetics.

[6]  Ian Collins,et al.  Objective, Quantitative, Data-Driven Assessment of Chemical Probes , 2017, bioRxiv.

[7]  Julian Blagg,et al.  Choose and Use Your Chemical Probe Wisely to Explore Cancer Biology , 2017, Cancer cell.

[8]  Barry R O'Keefe,et al.  The canSAR data hub for drug discovery. , 2016, The Lancet. Oncology.

[9]  Paul Workman,et al.  Distinctive Behaviors of Druggable Proteins in Cellular Networks , 2015, PLoS Comput. Biol..

[10]  John P. Overington,et al.  The promise and peril of chemical probes. , 2015, Nature chemical biology.

[11]  Amanda C. Schierz,et al.  canSAR: an updated cancer research and drug discovery knowledgebase , 2015, Nucleic Acids Res..

[12]  Mishal N. Patel,et al.  Objective assessment of cancer genes for drug discovery , 2012, Nature Reviews Drug Discovery.

[13]  Ian Collins,et al.  Probing the Probes: Fitness Factors For Small Molecule Tools , 2010, Chemistry & biology.